期刊文献+
共找到19篇文章
< 1 >
每页显示 20 50 100
Arabidopsis SOI33/AtENT8 Gene Encodes a Putative Equilibrative Nucleoside Transporter That Is Involved in Cytokinin Transport In Planta 被引量:16
1
作者 JiaqiangSUN NaoyaHIROSE +4 位作者 XingchunWANG PeiWEN LiXUE HitoshiSAKAKIBARA JianruZUO 《Journal of Integrative Plant Biology》 SCIE CAS CSCD 2005年第5期588-603,共16页
: The plant phytohormone cytokinin plays an important role in many facets of plant growth and development by regulating cell division and differentiation. Recent studies have shed significant light into the mechanisms... : The plant phytohormone cytokinin plays an important role in many facets of plant growth and development by regulating cell division and differentiation. Recent studies have shed significant light into the mechanisms of cytokinin metabolism and signaling. However, little is known about how the hormone is transported in planta, although it has been proposed that the hormone is presumably transported in nucleoside-conjugated forms. Here, we report the identification and characterization of cytokinin transporters in Arabidopsis. We previously reported that a gain-of-function mutation in the PGA22/AtIPT8 gene caused overproduction of cytokinins in planta. In an effort to screen for suppressor of pga 22/atipt 8 (soi) mutants, we identified a mutant soi33-1. Molecular and genetic analyses indicated that SOI33 encodes a putative equilibrative nucleoside transporter (ENT), previously designated as AtENT8. Members of this small gene family are presumed to be involved in the transport of nucleosides in eukaryotic cells. Under conditions of nitrogen starvation, loss-of-function mutations in SOI33/AtENT8 or in a related gene AtENT3 cause a reduced sensitivity to the nucleoside-type cytokinins isopentenyladenine riboside (iPR) and transzeatin riboside (tZR), but display a normal response to the free base-type cytokinins isopentenyladenine (iP) and trans-zeatin (tZ). Conversely, overexpression of SOI33/AtENT8 renders transgenic plants hypersensitive to iPR but not to iP. An in planta measurement experiment indicated that uptake efficiency of 3H-labeled iPR was reduced more than 40% in soi33 and atent3 mutants. However, a mutation in AtENT1 had no substantial effect on the cytokinin response and iPR uptake efficiency. Our results suggest that SOI33/ AtENT8 and AtENT3 are involved in the transport of nucleoside-type cytokinins in Arabidopsis. 展开更多
关键词 ARABIDOPSIS cytokinin transport equilibrative nucleoside transporter SOI33
原文传递
Identification of AtENT3 as the main transporter for uridine uptake in Arabidopsis roots 被引量:7
2
作者 Kun Ling Chen Min Xin Xu +6 位作者 Guang Yong Li Hui Liang Zong Liang Xia Xin Liu Ji Shu Zhang Ai Min Zhang Dao Wen Wang 《Cell Research》 SCIE CAS CSCD 2006年第4期377-388,共12页
Previous studies have shown that Arabidopsis equilibrative nucleoside transporters (AtENTs) possess transport activities when produced in yeast cells and are differentially expressed in Arabidopsis organs. Herein, w... Previous studies have shown that Arabidopsis equilibrative nucleoside transporters (AtENTs) possess transport activities when produced in yeast cells and are differentially expressed in Arabidopsis organs. Herein, we report further analysis on the nucleoside transport activities and transcriptional patterns of AtENT members. The recombinant proteins of AtENTs 3, 6, and 7, but not those of AtENTs 1, 2, 4, and 8, were found to transport thymidine with high affinity. Contrary to previ- ous suggestion that AtENT 1 may not transport uridine, this work showed that recombinant AtENT 1 was a pH-dependent and high-affinity transporter of uridine. When grown on MS plates, the AtENT3 knockout plants were more tolerant to the cytotoxic uridine analog 5-fluorouridine than wild-type plants and the knockout plants ofAtENT 1 or AtENT6. Con- sistent with this observation, the AtENT3 knockout line exhibited a significantly decreased ability to take up [^3H]uridine via the roots when compared with wild-type plants and the plants with mutated AtENT 1 or AtENT6. This indicates that AtENT3, but not AtENTs 1 and 6, is the main transporter for uridine uptake in Arabidopsis roots. The transcription of AtENTs 1, 3, 4, 6, 7, and 8 was regulated in a complex manner during leaf development and senescence. In contrast, the six AtENT members were coordinately induced during seed germination. This work provides new information on the transport properties of recombinant AtENT proteins and new clues for future studies of the in vivo transport activities and physiological functions of the different ENT proteins in Arabidopsis plants. 展开更多
关键词 ARABIDOPSIS equilibrative nucleoside transporter expression pattern nucleoside transport functional analysis
下载PDF
Addressing chemoresistance with a lipid gemcitabine nanotherapeutic strategy for effective treatment of pancreatic cancer
3
作者 Jiawei Hong Shiyun Xian +2 位作者 Shusen Zheng Hangxiang Wang Donghai Jiang 《Nano Research》 SCIE EI CSCD 2024年第9期8377-8388,共12页
Resistance to gemcitabine in pancreatic cancer poses a significant clinical challenge.Further investigation is warranted to assess whether nano-formulation strategy can be employed to enhance the sensitivity of resist... Resistance to gemcitabine in pancreatic cancer poses a significant clinical challenge.Further investigation is warranted to assess whether nano-formulation strategy can be employed to enhance the sensitivity of resistant strains to gemcitabine therapy.In this study,using gemcitabine-resistant pancreatic cancer cell lines,we examined the therapeutic potential of a gemcitabine nanodelivery platform and assessed the ability to overcome drug resistance against resistant strains.Silencing of human equilibrative nucleoside transporter 1(hENT1)led to reduced cellular uptake of gemcitabine,resulting in chemoresistance in pancreatic cancer.Gemcitabine nanoparticles circumvented the entry blockade caused by hENT1 silencing through endocytosis.Nanoparticle entry via clathrin-mediated endocytosis increased intracellular gemcitabine accumulation in gemcitabine-resistant pancreatic cancer cells.Moreover,gemcitabine nanoparticles are preferential in vivo delivery to tumor tissues,likely due to the enhanced permeability and retention effect.In comparison to free gemcitabine,gemcitabine nanoparticles demonstrate a more pronounced cytotoxic effect on gemcitabine-resistant pancreatic cancer cells,with favorable biosafety.This study improved the efficacy of gemcitabine through nanotechnology,providing a novel strategy to address gemcitabine-resistant pancreatic cancer. 展开更多
关键词 pancreatic cancer gemcitabine resistance gemcitabine nanoparticle human equilibrative nucleoside transporter 1
原文传递
双嘧达莫对胰腺癌细胞内抗肿瘤药物6-巯基嘌呤浓度的影响及6-巯基嘌呤的荧光分光光度法测定 被引量:4
4
作者 郑洪 鞠火晃先 朱广华 《分析试验室》 CAS CSCD 北大核心 2004年第8期1-4,共4页
建立了细胞内抗肿瘤药物6 巯基嘌呤的荧光光度分析新方法,系统地研究了在KMnO4氧化条件下酸度、温度、时间等因素对6 巯基嘌呤相对荧光强度的影响。在荧光激发波长310nm和发射波长413nm下,溶液中6 巯基嘌呤的荧光强度与其浓度在4.0×... 建立了细胞内抗肿瘤药物6 巯基嘌呤的荧光光度分析新方法,系统地研究了在KMnO4氧化条件下酸度、温度、时间等因素对6 巯基嘌呤相对荧光强度的影响。在荧光激发波长310nm和发射波长413nm下,溶液中6 巯基嘌呤的荧光强度与其浓度在4.0×10-11~4.0×10-6mol L范围内呈良好的线性关系,方法的检出限为8.2×10-12mol L。用建立的方法研究了不同浓度核苷载体阻断剂(双嘧达莫)对胰腺癌细胞内6 巯基嘌呤浓度的影响情况。统计学检验结果表明,细胞膜上核苷载体的阻断能提高细胞内抗肿瘤药物的浓度。 展开更多
关键词 双嘧达莫 胰腺癌细胞 6-巯基嘌呤 荧光分光光度法 核苷载体
下载PDF
Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinoma 被引量:3
5
作者 Aubrey L.Miller Patrick L.Garcia +2 位作者 Tracy L.Gamblin Rebecca B.Vance Karina J.Yoon 《Cancer Drug Resistance》 2020年第3期572-585,共14页
Aim:Gemcitabine is a frontline agent for locally-advanced and metastatic pancreatic ductal adenocarcinoma(PDAC),but neither gemcitabine alone nor in combination produces durable remissions of this tumor type.We develo... Aim:Gemcitabine is a frontline agent for locally-advanced and metastatic pancreatic ductal adenocarcinoma(PDAC),but neither gemcitabine alone nor in combination produces durable remissions of this tumor type.We developed three PDAC patient-derived xenograft(PDX)models with gemcitabine resistance(gemR)acquired in vivo,with which to identify mechanisms of resistance relevant to drug exposure in vivo and to evaluate novel therapies.Methods:Mice bearing independently-derived PDXs received 100 mg/kg gemcitabine once or twice weekly.Tumors initially responded,but regrew on treatment and were designated gemR.We used immunohistochemistry to compare expression of proteins previously associated with gemcitabine resistance[ribonucleotide reductase subunit M1(RRM1),RRM2,human concentrative nucleoside transporter 1(hCNT1),human equilibrative nucleoside transporter 1(hENT1),cytidine deaminase(CDA),and deoxycytidine kinase(dCK)]in gemR and respective gemcitabine-naïve parental tumors.Results:Parental and gemR tumors did not differ in tumor cell morphology,amount of tumor-associated stroma,or expression of stem cell markers.No consistent pattern of expression of the six gemR marker proteins was observed among the models.Increases in RRM1 and CDA were consistent with in vitro-derived gemR models.However,rather than the expected decreases of hCNT1,hENT1,and dCK,gemR tumors expressed no change in or higher levels of these gemR marker proteins than parental tumors.Conclusion:These models are the first PDAC PDX models with gemcitabine resistance acquired in vivo.The data indicate that mechanisms identified in models with resistance acquired in vitro are unlikely to be the predominant mechanisms when resistance is acquired in vivo.Ongoing work focuses on characterizing unidentified mechanisms of gemR and on identifying agents with anti-tumor efficacy in these gemR models。 展开更多
关键词 Gemcitabine resistance patient-derived xenograft ribonucleotide reductase subunit M1 ribonucleotide reductase subunit M2 human concentrative nucleoside transporter 1 human equilibrative nucleoside transporter 1 cytidine deaminase deoxycytidine kinase
原文传递
人体平衡型核苷转运蛋白的结构及应用研究进展 被引量:2
6
作者 郝振宇 刘瑞华 +1 位作者 王莹莹 Mark Bartlam 《中国细胞生物学学报》 CAS CSCD 2016年第6期736-743,共8页
通过参与合成和转运核苷及其类似物,人体中的平衡型核苷转运蛋白在生物体内参与了细胞发育、能量代谢和信号转导等众多生理生化过程,其研究对于癌症、病毒感染等相关疾病的治疗有着极为重要的意义。该文综述了该类蛋白质在人体内的发现... 通过参与合成和转运核苷及其类似物,人体中的平衡型核苷转运蛋白在生物体内参与了细胞发育、能量代谢和信号转导等众多生理生化过程,其研究对于癌症、病毒感染等相关疾病的治疗有着极为重要的意义。该文综述了该类蛋白质在人体内的发现历程、分类、结构和作用机制,并对于其在一些疾病治疗和药物开发方面的前景进行了展望。 展开更多
关键词 平衡型核苷转运蛋白 核苷转运 蛋白结构 转运机制
原文传递
Attempts to remodel the pathways of gemcitabine metabolism: Recent approaches to overcoming tumours with acquired chemoresistance 被引量:2
7
作者 Yuriko Saiki Shuto Hirota Akira Horii 《Cancer Drug Resistance》 2020年第4期819-831,共13页
Gemcitabine is a cytidine analogue frequently used in the treatment of various cancers.However,the development of chemoresistance limits its effectiveness.Gemcitabine resistance is regulated by various factors,includi... Gemcitabine is a cytidine analogue frequently used in the treatment of various cancers.However,the development of chemoresistance limits its effectiveness.Gemcitabine resistance is regulated by various factors,including aberrant genetic and epigenetic controls,metabolism of gemcitabine,the microenvironment,epithelial-to-mesenchymal transition,and acquisition of cancer stem cell properties.In many situations,results using cell lines offer valuable lessons leading to the first steps of important findings.In this review,we mainly discuss the factors involved in gemcitabine metabolism in association with chemoresistance,including nucleoside transporters,deoxycytidine kinase,cytidine deaminase,and ATP-binding cassette transporters,and outline new perspectives for enhancing the efficacy of gemcitabine to overcome acquired chemoresistance. 展开更多
关键词 GEMCITABINE CHEMORESISTANCE deoxycytidine kinase human equilibrative nucleoside transporter 1 cytidine deaminase ATP-binding cassette transporters METABOLISM
原文传递
Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts 被引量:1
8
作者 Stephan Kruger Michael Haas +5 位作者 Steffen Ormanns Sibylle Bchmann Jens T Siveke Thomas Kirchner Volker Heinemann Stefan Boeck 《World Journal of Gastroenterology》 SCIE CAS 2014年第31期10769-10777,共9页
Pancreatic ductal adenocarcinoma(PDA) is one of the major causes for cancer death worldwide. Treatment of metastatic disease remains challenging as only certain patients benefit from advances made with the intensified... Pancreatic ductal adenocarcinoma(PDA) is one of the major causes for cancer death worldwide. Treatment of metastatic disease remains challenging as only certain patients benefit from advances made with the intensified chemotherapy regimen folinic acid, irinotecan and oxaliplatin, the epidermal growth factor receptor inhibitor erlotinib or the recently FDA-approved nab-paclitaxel. Up to date, no established approach for prediction of treatment response or specific treatment allocation exists. Translational research was able to identify a number of potential biomarkers that might help to improve the dismal prognosis of PDA by facilitating upfront treatment allocation. This topic highlight is focused on current evidence on potential biomarkers for tumor biology, prognosis and prediction of treatment efficacy. 展开更多
关键词 Biomarker ERLOTINIB GEMCITABINE Human equilibrative nucleoside transporter 1 KRAS NAB-PACLITAXEL p53 Pancreatic cancer SMAD4 SPARC
下载PDF
核苷转运蛋白基因ENT3单核苷酸多态性与肺癌易感性的关系
9
作者 李雪飞 张颉 +1 位作者 张增利 周彩存 《中国肺癌杂志》 CAS 2010年第5期458-463,共6页
背景与目的核苷转运蛋白介导的核苷跨膜转运在调节细胞功能中发挥重要作用,可能是某些肿瘤的候选易感基因。本研究旨在探讨核苷转运蛋白基因ENT3单核苷酸多态性与肺癌易感性的关系。方法采用病例对照研究,收集2008年5月-2009年5月于上... 背景与目的核苷转运蛋白介导的核苷跨膜转运在调节细胞功能中发挥重要作用,可能是某些肿瘤的候选易感基因。本研究旨在探讨核苷转运蛋白基因ENT3单核苷酸多态性与肺癌易感性的关系。方法采用病例对照研究,收集2008年5月-2009年5月于上海市肺科医院就诊的原发性肺癌患者351例和同期住院的非肿瘤患者207例,应用AllGloTM探针结合实时荧光PCR方法分析肺癌组和对照组ENT3基因rs10999776多态位点的基因型分布情况,比较不同基因型与肺癌易感性的关系以及不同基因型联合吸烟对肺癌易感性的影响。肺癌组与对照组基因型和等位基因分布比较用χ2检验,以调整比值比及95%CI表示相对危险度,所有统计检验均为双侧概率检验,所有资料均用SPSS软件进行统计。结果肺癌患者rs10999776多态位点的CC、TC、TT基因型和C、T等位基因频率分布与对照组比较无统计学差异(P>0.05)。与非吸烟的野生型纯合子个体比较,携带突变等位基因T(TC+TT)的吸烟个体罹患肺癌的风险性明显增加,且吸烟≥30包/年者风险性更高,调整OR值分别为2.848(95%CI:1.536-4.879,P=0.005)、3.076(95%CI:2.308-6.741,P=0.001)。而对肺癌不同组织类型的分析发现,三种基因型的吸烟个体罹患肺鳞癌的风险性均增加,且携带突变等位基因T的个体风险性更高,调整OR值为6.066(95%CI:2.884-12.758,P<0.001)。而rs10999776(C>T)多态性联合吸烟对肺腺癌则无显著影响。结论核苷转运蛋白基因ENT3rs10999776多态性可能与肺鳞癌的发病风险相关,且与吸烟环境暴露存在一定的相互作用。 展开更多
关键词 核苷转运蛋白 单核苷酸多态性 探针 肺肿瘤 遗传易感性
下载PDF
晚期非小细胞肺癌患者手术标本人源核苷酸平衡转运体1蛋白表达与吉西他滨化疗敏感度的相关性分析 被引量:8
10
作者 楼君 盛誉 +1 位作者 吴闵丽 汤婉芬 《中国医药》 2015年第2期165-169,共5页
目的 评价非细小细胞肺癌(NSCLC)患者术后人源核苷酸平衡转运体1(hENT1)蛋白表达水平与吉西他滨化疗敏感度的相关性。方法筛选2007—2011年浙江金华广福医院肿瘤内科收治的经病理确诊为NSCLC并行手术切除后患者47例,完全随机分为G... 目的 评价非细小细胞肺癌(NSCLC)患者术后人源核苷酸平衡转运体1(hENT1)蛋白表达水平与吉西他滨化疗敏感度的相关性。方法筛选2007—2011年浙江金华广福医院肿瘤内科收治的经病理确诊为NSCLC并行手术切除后患者47例,完全随机分为GP组和NP组,GP组23例选用吉西他滨联合顺铂化疗,顺铂80 mg/m^2,第 1-3 天静脉滴注,吉西他滨 800-1 250 mg/m^2,第1、8天使用;NP组24例选用长春瑞滨联合顺铂化疗,顺铂用法同前,长春瑞滨 25 mg/m^2,第1、8天使用。对47例患者手术切除肺癌组织蜡块标本采用免疫组织化学链霉菌抗生物素蛋白过氧化物酶连结法检测hENT1蛋白表达水平。术后实施2周期以上吉西他滨或长春瑞滨化疗,随访患者的生存期,评价hENT1蛋白表达水平与2种化疗方案疗效相关性。结果GP组hENT1高表达患者13例,无进展生存期为(28±18)个月,中位无进展生存期32个月;NP组hENT1高表达患者14例,无进展生存期为(24±16)个月,中位无进展生存期22个月,差异均有统计学意义(P=0.042,P=0.037)。GP组hENT1低表达患者(10例)中位总生存期35个月,NP组hENT1低表达患者(10例)中位总生存期34个月比较,差异无统计学意义(P>0.05)。结论对于NSCLC患者, hENT1蛋白表达程度与吉西他滨的化疗敏感性相关。 展开更多
关键词 人源核苷酸平衡转运体1 非小细胞肺癌 晚期 吉西他滨 长春瑞滨
下载PDF
人类平衡型核苷转运蛋白1高表达晚期非小细胞肺癌患者术后应用不同剂量吉西他滨治疗的临床效果观察 被引量:7
11
作者 楼君 盛誉 +3 位作者 凌今 袁霞妹 吴闵丽 汤婉芬 《中国医药》 2015年第1期8-12,共5页
目的 观察晚期非小细胞肺癌(NSCLC)中人类平衡型核苷转运蛋白1(hENT1)高表达患者应用不同剂量吉西他滨治疗的临床效果.方法 选取2008年7月至2013年12月于浙江金华广福医院行晚期NSCLC手术后,病理确诊晚期NSCLC患者,采用免疫组织化... 目的 观察晚期非小细胞肺癌(NSCLC)中人类平衡型核苷转运蛋白1(hENT1)高表达患者应用不同剂量吉西他滨治疗的临床效果.方法 选取2008年7月至2013年12月于浙江金华广福医院行晚期NSCLC手术后,病理确诊晚期NSCLC患者,采用免疫组织化学SP法检测肺癌组织中hENT1抗体的表达水平.62例hENT1高表达患者入组,按随机数字表分组法分为对照组(30例)和观察组(32例).对照组采用常规剂量吉西他滨(1 000 mg/m2)联合顺铂进行化疗,观察组用低剂量吉西他滨(250 mg/m2)联合顺铂进行化疗,观察2组近期疗效、化疗不良反应.采用生活质量调查核心量表QLQ-C30和肺癌专用量表QLQ-LCl3比较2组化疗后生活质量.结果 对照组和观察组近期有效率和疾病控制率差异无统计学意义[43.3% (13/30)比46.9% (15/32),76.9% (23/30)比81.2%(26/32)](x2 =0.08,x2 =0.20,P>0.05).观察组Ⅲ、Ⅳ度白细胞减少、血小板减少及恶心、呕吐发生率低于对照组,差异有统计学意义(P<0.05);除角色功能外,观察组化疗后总体生活评分及躯体功能、情绪功能、认知功能、社会功能、经济状况各项评分均优于对照组[(54±20)分比(54±16)分,(72±25)分比(62 ±20)分、(85 ±20)比(72±19)分、(76±28)分比(62±25)分、(61 ±24)分比(49 ±30)分、(36±24)分比(56±21)分],差异均有统计学意义(均P<0.05).观察组除乏力症状外其他症状评分均优于对照组(P<0.05).结论 对于晚期NSCLC术后hENT1高表达患者,在保证化疗效果的同时,相对于常规剂量吉西他滨,低剂量用药可有效降低化疗过程中不良反应,提高患者的生活质量. 展开更多
关键词 非小细胞肺 人类平衡型核苷转运蛋白1 吉西他滨 剂量
下载PDF
Molecular characterization of circulating tumor cells in pancreatic ductal adenocarcinoma:potential diagnostic and prognostic significance in clinical practice 被引量:5
12
作者 Xudong Zhao Yongsu Ma +4 位作者 Xiu Dong Zhengkui Zhang Xiaodong Tian Xiaohang Zhao Yinmo Yang 《Hepatobiliary Surgery and Nutrition》 SCIE 2021年第6期796-810,I0006,I0007,共17页
Background:The clinical value of heterogeneous sub-populations of circulating tumor cells(CTCs)in pancreatic ductal adenocarcinoma(PDAC)remains unclear.Methods:Peripheral blood samples were obtained from 67 PDAC patie... Background:The clinical value of heterogeneous sub-populations of circulating tumor cells(CTCs)in pancreatic ductal adenocarcinoma(PDAC)remains unclear.Methods:Peripheral blood samples were obtained from 67 PDAC patients.CTCs were isolated by employing CD45 negative enrichment technique and further characterized for epithelial to mesenchymal transition(EMT)or human equilibrative nucleoside transporter-1(hENT-1).The relationships between CTCs sub-phenotypes with clinicopathological factors or post-operative recurrence in PDAC patients were analyzed.Results:EMT related CTCs could be isolated and identified from the 81%of patients(54/67),and both the total count(median:5 vs.17/mL,P<0.0001)and M-CTC percentage(median:0.2 vs.0.345,P=0.0244)of CTCs could differentiate local/regional with metastatic disease.Multivariate analysis showed that both AJCC stage(P=0.025)and M-CTC percentage(P=0.001)were independent prognostic indicators of recurrence free survival(RFS)in resected patients.Moreover,Kaplan-Meier survival analysis showed that M-CTC after 2 courses of chemotherapy was significantly associated with inferior RFS(49.5 weeks vs.undefined,P=0.0288).No significant correlation in hENT-1 expression was found between CTCs and matched tumor tissues,and further multivariate analysis suggested hENT-1 expression in CTCs as independent prognostic factor for RFS(P=0.016).Patients with low hENT-1 expression in CTCs had decreased RFS(32 weeks vs.undefined,P=0.0337).Conclusions:CTCs could be the promising diagnostic biomarkers in PDAC patients,and phenotypic profiling of CTCs based on EMT or hENT-1 could help establish novel prognostic biomarkers in resected patients undergoing adjuvant gemcitabine-based chemotherapy. 展开更多
关键词 Circulating tumor cells(CTCs) Pancreatic ductal adenocarcinoma(PDAC) Epithelial to mesenchymal transition(EMT) human equilibrative nucleoside transporter-1(hENT-1)
原文传递
ENT1在人肝癌细胞中的表达特征及临床意义 被引量:1
13
作者 蒋星星 傅华群 +1 位作者 巢映辉 刘征宇 《世界华人消化杂志》 CAS 北大核心 2011年第20期2104-2108,共5页
目的:探讨ENT1在人肝癌细胞株中的表达特征及其临床意义.方法:人肝癌细胞HuH-7、HepG2、Hep3B并选择人乳腺癌细胞MCF-7为对照,采用免疫荧光法检测细胞中ENT1的定位表达;RT-PCR法检测细胞中ENT1mRNA的表达;CDKs特异性抑制剂干预人肝癌细... 目的:探讨ENT1在人肝癌细胞株中的表达特征及其临床意义.方法:人肝癌细胞HuH-7、HepG2、Hep3B并选择人乳腺癌细胞MCF-7为对照,采用免疫荧光法检测细胞中ENT1的定位表达;RT-PCR法检测细胞中ENT1mRNA的表达;CDKs特异性抑制剂干预人肝癌细胞HuH-7的细胞周期,RT-PCR法检测细胞不同周期ENT1mRNA的表达特征.结果:3株人肝癌细胞膜上均可见ENT1的表达;肝癌细胞中ENT1mRNA的表达水平均高于乳腺癌细胞;不同肝癌细胞株中ENT1mRNA的表达水平存在差异(HuH-7:0.756±0.019,HepG2:0.469±0.041,Hep3B:0.580±0.030,MCF-7:0.356±0.029);肝癌细胞被阻滞在G0/G1期后,ENT1mRNA的表达水平明显上调(0.737±0.017vs0.345±0.027,P<0.05).结论:人肝癌细胞膜上普遍存在较高的ENT1表达,不同的肝癌细胞及不同的细胞周期其表达均存在差异.ENT1在人肝癌细胞中的表达特征对临床化疗策略具有潜在的临床价值,并为认识肝癌的耐药机制提供新的思路. 展开更多
关键词 核苷载体 肝癌细胞 平衡型核苷载体1
下载PDF
SKM-1细胞地西他滨耐药机制中hENT1功能的研究 被引量:1
14
作者 史文慧 吴凌云 +3 位作者 郭娟 许峰 常春康 李晓 《中华血液学杂志》 CAS CSCD 北大核心 2015年第5期408-412,共5页
目的 观察干扰1型平衡核苷转运体(human equilibrative nucleoside transporters 1,hENT1)表达后,地西他滨(DAC)对人骨髓增生异常综合征(MDS)细胞系SKM-1细胞的增殖、凋亡和去甲基化的影响.方法 采用慢病毒干扰技术沉默SKM-1细胞... 目的 观察干扰1型平衡核苷转运体(human equilibrative nucleoside transporters 1,hENT1)表达后,地西他滨(DAC)对人骨髓增生异常综合征(MDS)细胞系SKM-1细胞的增殖、凋亡和去甲基化的影响.方法 采用慢病毒干扰技术沉默SKM-1细胞中hENT1,采用RT-PCR方法检测靶细胞内hENT1 mRNA表达水平,采用CCK-8法检测不同浓度DAC(0.5、1、5 μmol/L)作用24、48及72 h对hENT1沉默SKM-1细胞的增殖抑制情况,应用流式细胞术及Western blot法观察DAC诱导的凋亡情况,采用甲基化特异性PCR检测p15^INK4B去甲基化水平,分析hENT1沉默后DAC的去甲基化作用.结果 hENT1干扰组hENT1 mRNA表达水平(0.253±0.030)相对于对照组(1.000±0.091)显著降低(P<0.01);经0.5、1、5μmol/L DAC作用24、48及72 h后,相对于同时期对照组,hENT1干扰组的增殖抑制率均明显下降(P<0.05),其中5 μmol/L DAC作用72 h最为明显,hENT1干扰组和对照组分别为(49.41±4.02)%和(33.03±2.47)%(P=0.007);hENT1干扰组Caspase-3的剪切体水平及Annexin Ⅴ+细胞比例减少,并且p15^INK4B去甲基化水平也显著降低.结论 hENT1沉默后SKM-1细胞对DAC诱导的凋亡及去甲基化作用敏感性下降. 展开更多
关键词 平衡核苷转移子1 地西他滨 SKM-1细胞 抗药性
原文传递
5-溴脱氧尿嘧啶核苷标记酵母基因组DNA的方法 被引量:2
15
作者 赵宏宇 赵玥 +2 位作者 王建英 李珺 蔡禄 《中国生物工程杂志》 CAS CSCD 北大核心 2012年第1期81-86,共6页
胸腺嘧啶类似物5-溴脱氧尿嘧啶核苷(BrdU)标记技术是一种研究DNA复制、修复等生命过程的有效手段。由于酿酒酵母(Saccharomyces cerevisiae)中缺少胸腺嘧啶核苷酸补救途径,胞外BrdU不能有效的渗入到基因组中,使该技术在酿酒酵母中的应... 胸腺嘧啶类似物5-溴脱氧尿嘧啶核苷(BrdU)标记技术是一种研究DNA复制、修复等生命过程的有效手段。由于酿酒酵母(Saccharomyces cerevisiae)中缺少胸腺嘧啶核苷酸补救途径,胞外BrdU不能有效的渗入到基因组中,使该技术在酿酒酵母中的应用受到极大制约。通过在基因组中引入单纯疱疹病毒胞苷激酶(HSV-TK)和人类平衡核苷转运蛋白(hENT1)基因,工作建立了BrdU标记酵母基因组DNA的方法。在生长对数中期加入0.2mg/ml BrdU,离体检测法检测发现,标记3h的荧光信号较1h、5h时强;胞内检测法结果显示,标记3h时55.3%的基因组DNA中能够渗入BrdU。该工作为酿酒酵母DNA复制、修复等方面提供了直接有效的研究方法。 展开更多
关键词 5-溴脱氧尿嘧啶核苷 单纯疱疹病毒胞苷激酶 人类平衡核苷转运蛋白 酿酒酵母 DNA复制
原文传递
低剂量吉西他滨化疗在溶质载体家族1号基因T1288A突变型胰腺癌中的疗效 被引量:1
16
作者 周鸿鲲 王晓光 +3 位作者 宋政炜 费建国 梁霄 蔡秀军 《中华实验外科杂志》 CAS CSCD 北大核心 2018年第3期539-542,共4页
目的探讨低剂量吉西他滨化疗在溶质载体家族1号基因(SLC29A1)T1288A突变型胰腺癌患者中的疗效及不良反应。方法以收治的SLC29A1基因T1288A突变型中晚期胰腺癌患者共72例,随机归入实验组(低剂量吉西他滨,600 mg/m2)36例和对照组(... 目的探讨低剂量吉西他滨化疗在溶质载体家族1号基因(SLC29A1)T1288A突变型胰腺癌患者中的疗效及不良反应。方法以收治的SLC29A1基因T1288A突变型中晚期胰腺癌患者共72例,随机归入实验组(低剂量吉西他滨,600 mg/m2)36例和对照组(标准剂量吉西他滨,1 000 mg/m^2)36例,观察评价化疗疗效及不良反应。结果疗效比较中,实验组与对照组各项指标比较差异均无统计学意义。不良反应比较中,实验组白细胞减少、血小板减少、红细胞减少、恶心呕吐、肝损害、腹泻、皮疹和瘙痒、流感样症状发生率分别为3例(8.3%)、3例(8.3%)、4例(11.1%)、6例(16.7%)、2例(5.6%)、3例(8.3%)、1例(2.8%)、1例(2.8%);对照组为12例(33.3%)、15例(41.7%)、13例(36.1%)、20例(55.6%)、2例(5.6%)、4例(11.1%),1例(2.8%)、1例(2.8%),不良反应中白细胞减少(P=0.009)、血小板减少(P=0.001)、红细胞减少(P=0.013)、恶心呕吐(P=0.001),差异有统计学意义。通过随访观察两组6个月和1年生存期比较差异无统计学意义。结论对于SLC29A1基因T1288A突变型胰腺癌患者,在一定范围内给予低剂量吉西他滨化疗,在不降低化疗疗效同时可有效减少化疗不良反应。 展开更多
关键词 吉西他滨 胰腺癌 溶质载体家族1号基因 人平衡型核苷转运蛋白1
原文传递
MiR-26b靶向hENT1通过RhoA/ROCK-1通路调控肺癌细胞的侵袭和迁移 被引量:1
17
作者 高阳 杨帆 《中南大学学报(医学版)》 CAS CSCD 北大核心 2017年第7期755-761,共7页
目的:探讨miR-26b在肺癌组织中的表达及miR-26b在肺癌细胞侵袭和迁移过程中的作用及其机制。方法:q PCR检测肺癌和正常肺组织中miR-26b的表达情况;荧光素酶报告基因检测miR-26b与人平衡核苷转运蛋白1(human equilibrative nucleoside tr... 目的:探讨miR-26b在肺癌组织中的表达及miR-26b在肺癌细胞侵袭和迁移过程中的作用及其机制。方法:q PCR检测肺癌和正常肺组织中miR-26b的表达情况;荧光素酶报告基因检测miR-26b与人平衡核苷转运蛋白1(human equilibrative nucleoside transporter 1,hENT1)的相互作用;Transwell侵袭试验检测miR-26b的表达对肺癌细胞侵袭能力的影响;划痕试验检测miR-26b的表达对肺癌细胞迁移能力的影响;Western印迹检测h ENT1,ROCK-1,Rho A蛋白的表达情况;鬼笔环肽染色观察miR-26b-mimic处理后细胞骨架的变化情况;裸鼠皮下成瘤试验检测miR-26b-mimic对肺癌成瘤大小及体积的影响。结果:与正常肺组织相比,肺癌组织中miR-26b表达明显降低;且晚期、低分化和有淋巴结转移的肺癌组织miR-26b表达明显较早期、高分化和无淋巴结转移的肺癌组织低;miR-26b能与h ENT1的3'-UTR特异性结合;miR-26b可以调控肺癌A549细胞的侵袭迁移能力;过表达miR-26b可以抑制h ENT1,ROCK-1,Rho A的表达;miR-26b-mimic处理后,F-actin染色明显减少,细胞膜皱褶形成明显减少,伪足形成明显减少;裸鼠皮下成瘤试验显示:miR-26b-mimic处理后肿瘤体积和质量明显减小。结论:MiR-26b在肺癌中表达明显降低,且跟肺癌分期、分级及淋巴结转移与否密切相关,同时靶向h ENT1通过Rho A/ROCK-1信号通路调控肺癌细胞的侵袭和迁移。 展开更多
关键词 miR-26b 肺癌 人平衡核苷转运蛋白1 ROCK-1 Transwell侵袭试验
下载PDF
人平衡核苷转运体1在肿瘤性疾病中的研究进展
18
作者 熊冬霞(综述) 文飞球(审校) 《国际儿科学杂志》 2019年第11期827-830,共4页
人平衡核苷转运体1(human equilibrative nucleoside transporter 1,hENT1)是介导核苷、核碱基和核苷类化疗药转运的多元整合膜蛋白,在人体内主要分布在细胞膜上。hENT1通过易化扩散维持细胞内核苷稳态及核苷类化疗药物在细胞内的浓度,... 人平衡核苷转运体1(human equilibrative nucleoside transporter 1,hENT1)是介导核苷、核碱基和核苷类化疗药转运的多元整合膜蛋白,在人体内主要分布在细胞膜上。hENT1通过易化扩散维持细胞内核苷稳态及核苷类化疗药物在细胞内的浓度,从而影响DNA和RNA合成、细胞信号传导、代谢调节及肿瘤的化疗效果。该文就hENT1结构与功能、在肿瘤组织分布、与核苷类化疗药敏感性及肿瘤预后的关系方面作一综述。 展开更多
关键词 人平衡核苷转运体1 核苷类化疗药 肿瘤
原文传递
人平衡核苷转运体1与胰腺癌化疗耐药性的关系
19
作者 肖剑春 张太平 赵玉沛 《国际外科学杂志》 2012年第10期698-701,共4页
吉西他滨是临床胰腺癌化疗首选药物之一,然而患者对吉西他滨的化疗敏感性并不相同,部分患者对吉西他滨原发或继发耐药。人平衡核苷转运体1是介导吉西他滨进入肿瘤细胞的主要转运体,人平衡核苷转运体1在在不同患者肿瘤细胞中的表达差... 吉西他滨是临床胰腺癌化疗首选药物之一,然而患者对吉西他滨的化疗敏感性并不相同,部分患者对吉西他滨原发或继发耐药。人平衡核苷转运体1是介导吉西他滨进入肿瘤细胞的主要转运体,人平衡核苷转运体1在在不同患者肿瘤细胞中的表达差异性是造成胰腺癌吉西他滨化疗耐药的原因之一。 展开更多
关键词 人平衡核苷转运体1 胰腺肿瘤 药物治疗 耐药性
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部